La cadena de opciones muestra datos clave de las opciones de acciones de Enerpac Tool Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Enerpac Tool Group..

Enerpac Tool Group (NYSE:EPAC) Bolsa, Cadena de Opciones

Enerpac Tool Group

Enerpac Tool Group provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company has one reportable segment, the Industrial Tools & Services (IT&S) Segment. The IT&S segment is primarily engaged in the design, manufacture, and distribution of branded hydraulic and mechanical tools and in providing services and tool rental to the refinery/petrochemical; general industrial; industrial maintenance, repair, and operations (MRO); machining & manufacturing; power generation; infrastructure; mining; and other markets. Geographically, the company has operations in Algeria, Australia, Brazil, France, Germany, Kazakhstan, India, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, and the United Arab Emirates.

Enerpac Tool Group Corp

The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) provided a look at multi-year guidance, which surprised analysts and resulted in price targets being raised after the company&#8217;s <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">fourth-quarter financial results. </a>
The Disney Analysts:
<ul>
<li>Guggenheim analyst Michael Morris maintained a Buy rating on Disney and raised the price target from $110 to $130.</li>
<li>Macquarie analyst Tim Nollen maintained a Neutral rating and raised the price target from $91 to $110.</li>
<li>Goldman Sachs analyst Michael Ng maintained a Buy rating and raised the price target from $125 to $135.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/11/41953395/disney-q4-earnings-preview-disney-profitability-deadpool-box-office-success-top-items-to-watch">Disney Q4 Earnings Preview: Disney+ Profitability, Deadpool Box Office Success Top Items To Watch</a>
Guggenheim on DIS: Multi-year guidance provided by Disney could help instill confidence in a path for long-term growth, Morris said in a new investor note.
The analyst said fourth-quarter results saw direct-to-consumer profit come in ahead of estimates with linear networks lagging.
"Key incremental item is the detailed, multi-year financial guidance, which includes FY25 EPS growth ahead of consensus and acceleration to double-digit growth in 2026 and 2027," Morris said.
The analyst said entertainment, DTC and studio growth are expected to offset the continued pressure on linear networks.
"We see ESPN Flagship launch, consolidated entertainment growth, parks profit expansion and succession clarity as core components of the BUY thesis into 2025."
Macquarie on DIS: There was a lot to like in Disney's fourth-quarter results and guidance, Nollen said in a new investor note.
"Disney's F4Q report contained positive and detailed guidance for FY25-27 that speak to its long-term potential," Nollen said.
DTC profitability, the success of big blockbuster films, and advertising stability were highlights for the analyst in the fourth quarter.
The analyst also said Disney's guidance was richer than usual.
While the quarter was strong, the analyst remains Neutral, given near-term risks and concerns about the stock&#8217;s valuation, with shares trading at 20x PE and 12x FY25 EV/EBITDA.
Nollen is concerned that the ESPN DTC Flagship launch could include trade-offs with linear subscribers.
"Disney is the one traditional media company that we can be confident will transition successfully to streaming. The positive detailed guidance is encouraging, and sentiment could carry the stock."
Goldman Sachs on DIS: Theme park recovery, DTC strength and the multi-year outlook were highlights in the fourth quarter for Ng.
"DIS provided a 3-year outlook that exceeded even our above-consensus expectations," Ng said.
The analyst said the guidance for fiscal 2025, 2026 and 2027 was better than expected and shows strength across several key segments.
"DIS expects its F2025 results to reflect progression in profitably scaling its streaming businesses with attractive margins and continued investments to grow its Experiences business."
The analyst is watching the launch of ESPN Flagship, upcoming movies like "Moana 2" and "Mufasa,&#8221; the company's upcoming theme park expansions and new cruise ships for future growth.
"We are Buy-rated on DIS as we believe the company is a high-quality EPS compounder."
DIS Price Action: Disney stock is up 3.6% to $113.07 on Friday versus a 52-week trading range of $83.91 to $123.74. Disney stock is up 25% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41999904/disney-ceo-bob-iger-slams-the-brakes-on-new-ma-amid-comcasts-cable-spinoff-we-dont-need-more-assets-to-compete-in-todays-disruptive-media-landscape">Bob Iger Slams The Brakes On New M&amp;A Amid Comcast&#8217;s Cable Spinoff: Disney Doesn&#8217;t &#8216;Really Need More Assets&#8217; To Compete</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Entertainment

Price Target

Reiteration

Sports

Analyst Ratings

Trading Ideas

Disney Q4 Report Had 'A Lot To Like': Analyst Calls It A 'High-Quality' Profit Growth Performer

RBC Capital analyst Rishi Jaluria reiterates NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and maintains $260 price target.

News

NICE

RBC Capital Reiterates Outperform on NICE, Maintains $260 Price Target

WIIM

IMNM

Immunome shares are trading lower on continued weakness after the company on Wednesday reported worse-than-expected Q3 EPS results.

DA Davidson analyst Manuel Navas maintains Provident Finl Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFS#NYSE">PFS</a>) with a Buy and raises the price target from $24 to $27.

DA Davidson Maintains Buy on Provident Finl Servs, Raises Price Target to $27

RBC Capital analyst Elvira Scotto reiterates Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) with a Sector Perform and maintains $19 price target.

RBC Capital Reiterates Sector Perform on Plains All American, Maintains $19 Price Target

Loop Capital analyst Alan Gould maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $120 to $125.

Loop Capital Maintains Buy on Walt Disney, Raises Price Target to $125

RBC Capital analyst Sabahat Khan reiterates Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) with a Outperform and maintains $52 price target.

TTEK

RBC Capital Reiterates Outperform on Tetra Tech, Maintains $52 Price Target

PepsiCo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) shares are trading lower by 3.75% to $158.97 Friday afternoon. Shares of beverage and packaged food stocks are trading lower after President-elect Donald Trump indicated he would nominate Robert F. Kennedy Jr. to <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">lead the HHS</a>.
What To Know: Kennedy's history of criticizing corporate influence on public health has raised concerns about potential regulatory shifts targeting key sectors of PepsiCo&#8217;s diversified business.
As a global leader in beverages and snacks, PepsiCo's portfolio includes sugary soft drinks, such as Pepsi and Mountain Dew, alongside snacks like Doritos and Lay's, as well as healthier offerings under brands like Quaker and Naked Juice. 
Analysts warn that Kennedy's stance on the &#8220;industrial food complex&#8221; could lead to stricter rules on sugar content, marketing practices, and nutritional labeling.
With U.S. consumers already <a href="https://www.benzinga.com/general/biotech/24/07/39656549/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo">gravitating toward healthier options</a>, any heightened regulatory scrutiny on sugary beverages and processed snacks could pressure PepsiCo's core businesses. In addition, possible restrictions on marketing to children, a key demographic for many of its products, could further impact growth.
Read Also: <a href="https://www.benzinga.com/news/retail-sales/24/11/42008180/october-retail-sales-top-expectations-as-us-consumers-increase-tech-spending">October Retail Sales Top Expectations As US Consumers Increase Tech Spending</a>
<h2 class="wp-block-heading">How To Buy PEP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in PepsiCo&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PEP has a 52-week high of $183.39 and a 52-week low of $158.03.

Why Pepsi Stock Is Falling

Loop Capital analyst Jeffrey Stevenson maintains BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) with a Buy and raises the price target from $18 to $20.

Loop Capital Maintains Buy on BrightView Hldgs, Raises Price Target to $20

DA Davidson analyst Michael Shlisky maintains Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) with a Buy and maintains $82 price target.

DA Davidson Maintains Buy on Miller Industries, Maintains $82 Price Target

RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Sector Perform and maintains $4 price target.

BLUE

RBC Capital Reiterates Sector Perform on bluebird bio, Maintains $4 Price Target

Maxim Group analyst Jason McCarthy maintains Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) with a Buy and raises the price target from $60 to $110.

BLTE

Maxim Group Maintains Buy on Belite Bio, Raises Price Target to $110

In the tech world, few <a href="https://www.benzinga.com/markets/24/10/41457050/bill-gates-once-said-he-was-so-jealous-of-apples-steve-jobs-and-labeled-him-a-genius-and-wizard-no-o">rivalries are as legendary</a> as that between Apple's Steve Jobs and <a href="https://www.benzinga.com/general/education/24/10/41580000/bill-gates-turns-69-5-things-you-might-not-know-about-microsoft-co-founder">Microsoft's Bill Gates</a>. The two pioneers changed the personal computer industry and how we use technology by pushing the envelope in their special ways for decades. However, when asked about his relationship with Gates in a rare joint interview, Jobs didn&#8217;t respond with competitiveness or rivalry – instead, he quoted a line from a Beatles song.
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
During the 2007 <a href="https://www.youtube.com/watch?v=wvhW8cp15tk">interview</a>, Jobs and Gates reminisced about their long history in the industry. They laughed, remembering their early years when they were frequently the youngest in the room. Gates noted how it was always wonderful to see someone like Jobs persevere through the many challenges and trends offered by the rapidly changing computer sector.&nbsp;
Jobs, known for his passion for music, quoted The Beatles' reflective line: "You and I have memories longer than the road that stretches out ahead,&#8221; before adding, &#8220;And that&#8217;s clearly true here.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When Steve Jobs was asked about his relationship with competitor and business rival, Bill Gates, he answered with a lyric from this reflective Beatles song: <a href="https://t.co/CovfClpMim">pic.twitter.com/CovfClpMim</a>
&mdash; The Beatles Earth (@BeatlesEarth) <a href="https://twitter.com/BeatlesEarth/status/1856357686956237143?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
The lyric from The Beatles' "Two of Us" <a href="https://www.youtube.com/watch?v=cLQox8e9688">song</a> perfectly captured the sentiment. For all their competition, Jobs and Gates shared a deep mutual respect. The song is about friendship, shared memories and a sense of journey – and that's exactly how Jobs saw his connection with Gates. After all, they'd both been through the ups and downs of building billion-dollar companies, watching trends come and go and surviving the intense pressures of leading groundbreaking tech firms.
It was a moment that showed the softer side of their relationship and that despite being rivals, Jobs and Gates weren't just competing tech CEOs – they were two individuals who'd shared a unique journey in an industry they helped to shape. Their antagonism had subsided into camaraderie based on mutual knowledge of what it required to get to where they were, shared experiences and the <a href="https://www.benzinga.com/personal-finance/24/10/41340693/bill-gates-saved-rival-apple-from-bankruptcy-by-investing-150-million-steve-jobs-thanked-him-pub">rare act of cooperation</a>.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Back in the late '70s and early '80s, Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was working hard to get its personal computers into homes, schools and offices, aiming to make computers friendly, accessible and even stylish. Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), on the other hand, was all about software under Gates&#8217; direction. Gates aimed to install Microsoft&#8217;s operating system on as many machines as possible, including IBM, Apple&#8217;s main rival. And a long-standing rivalry was sparked by this action.&nbsp;
Microsoft's Windows operating system, <a href="https://www.benzinga.com/tech/24/11/41872487/bill-gates-introduced-windows-41-years-ago-today-heres-how-much-youd-have-if-you-invested-1000-in-microsoft-when-it-went-public">introduced in 1983</a>, was strikingly similar to Apple's Mac OS and Jobs was not happy about it. He famously accused Gates of copying Apple&#8217;s interface, saying that Microsoft had no shame in borrowing ideas.
Ultimately, this brief Beatles reference from Jobs was a reminder of the humanity behind the industry giants. For those who grew up with either an Apple device or Microsoft software – most of us have used both – their partnership and rivalry have always felt like a part of our own experience with technology.
Read Next:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Startups

AAPL

MSFT

When Asked About His Business Rivalry With Bill Gates, Steve Jobs Replied With A Beatles Lyric From This Reflective Song

U.S. stocks traded lower midway through trading, with the S&amp;P 500 falling by over 1% on Friday.
The Dow traded down 0.90% to 43,356.00 while the NASDAQ fell 2.26% to 18,676.22. The S&amp;P 500 also fell, dropping, 1.42% to 5,864.40.
Check This Out: <a href="https://www.benzinga.com/24/11/42005109/top-4-utilities-stocks-that-may-keep-you-up-at-night-this-quarter">Top 4 Utilities Stocks That May Keep You Up At Night This Quarter</a>
Leading and Lagging Sectors Energy shares rose by 0.4% on Friday.
In trading on Friday, information technology shares fell by 1.9%.
Top Headline
U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, and toping market estimates of 0.3%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>The Arena Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) shares shot up 232% to $1.89 after it announced its first ever profitable quarter.</li>
<li>Shares of Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) got a boost, surging 49% to $19.80. Bloom Energy announced a 1 GW fuel cell deal with AEP, providing clean power for AI Data Centers.</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares were also up, gaining 90% to $1.6601 after the company announced a $400,000 contract to supply autonomous cleaning robots at Singapore&#8217;s International Airport Terminal.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares dropped 78% to $0.3581 after the company announced it will wind down its operations.</li>
<li>Shares of Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) were down 73% to $0.0932 after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.</li>
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) was down, falling 33% to $1.1724 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $68.35 while gold traded up 0.2% at $2,579.20.
Silver traded up 0.7% to $30.79 on Friday, while copper rose 0.8% to $4.1220.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.58%, Germany's DAX fell 0.16% and France's CAC 40 fell 0.26%. Spain's IBEX 35 Index gained 0.82%, while London's FTSE 100 fell 0.06%.
The annual inflation rate in Italy increased to 0.9% in October versus 0.7% in the prior month, while France&#8217;s annual inflation rate rose to 1.2% in October. The GDP in the UK grew by 1% year-over-year during the third quarter.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 gaining 0.28%, Hong Kong's Hang Seng Index falling 0.05% and China's Shanghai Composite Index dipping 1.45%.
Hong Kong's economy expanded by 1.8% year-over-year in the third quarter compared to a 3.2% increase in the previous period. China&#8217;s retail sales rose by 4.8% year-over-year in October, while industrial production rose by 5.3% year-over-year in October.
Economics
<ul>
<li>The NY Empire State Manufacturing Index surged to 31.2 in November versus -11.9 in the previous month and topping market estimates of -0.7.</li>
<li>U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October.</li>
<li>U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, and toping market estimates of 0.3%.</li>
<li>U.S. industrial production declined by 0.3% in October compared to a revised 0.5% declined in September.</li>
<li>U.S. business inventories rose 0.1% month-over-month in September compared to a 0.3% gain in August and versus market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42007351/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

AREN

EYEN

RVYL

SPPL

TFFP

S&P 500 Down Over 1%; US Retail Sales Top Expectations

Maxim Group analyst Allen Klee maintains Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) with a Buy and lowers the price target from $8 to $5.

DLPN

Maxim Group Maintains Buy on Dolphin Entertainment, Lowers Price Target to $5

RBC Capital analyst Tom Narayan maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and raises the price target from $249 to $313.

TSLA

RBC Capital Maintains Outperform on Tesla, Raises Price Target to $313

DA Davidson analyst Linda Bolton Weiser maintains Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) with a Neutral and raises the price target from $12 to $13.

DA Davidson Maintains Neutral on Sally Beauty Holdings, Raises Price Target to $13

Maxim Group analyst Michael Diana maintains FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) with a Buy and raises the price target from $2 to $4.

FPAY

Maxim Group Maintains Buy on FlexShopper, Raises Price Target to $4

DA Davidson analyst Michael Baker maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Neutral and maintains $45 price target.

DA Davidson Maintains Neutral on Advance Auto Parts, Maintains $45 Price Target

This article was originally published on <a href="https://cannabis.net/blog/news/no-spliff-for-you-rescheduling-cannabis-could-allow-for-hemp-tobacco-cigarettes-but-not-weed-an">Cannabis.net</a> and appears here with permission.
Marijuana rescheduling could permit CBD from hemp in tobacco, but not weed!
A recent report from the Congressional Research Service (CRS) has ignited discussions about the potential for incorporating hemp-<a href="https://cannabis.net/blog/medical/study-says-cbd-could-be-your-way-out-of-a-tobacco-addiction">derived cannabidiol (CBD) into tobacco products</a>, contingent upon the anticipated rescheduling of marijuana. As public perceptions of cannabis evolve and regulatory frameworks shift, this development could have profound implications for both the cannabis and tobacco industries, as well as for public health initiatives aimed at reducing smoking-related harm.
<h3>Understanding&nbsp;The Context Of Marijuana Rescheduling</h3>
Historically, marijuana has been classified as a Schedule I substance under the Controlled Substances Act (CSA), indicating that it is viewed as having no accepted medical use and a high potential for abuse. However, with growing evidence supporting the medicinal benefits of cannabis and changing public perceptions, there has been increasing momentum toward rescheduling marijuana. In August 2023, the Department of Health and Human Services (HHS) recommended that marijuana be reclassified to Schedule III, which would acknowledge its medical applications and significantly alter the regulatory landscape surrounding cannabis.
<h3>Implications Of Rescheduling</h3>
If marijuana is rescheduled to Schedule III, it would not only ease restrictions on research and development but also open new avenues for product innovation. According to the CRS report, while marijuana itself would still be prohibited in food, dietary supplements, or cosmetics,&nbsp;<a href="https://cannabis.net/blog/smoke/are-cbd-cigarettes-the-middle-ground-between-cannabis-and-tobacco">hemp-derived CBD could be used as an additive in tobacco</a>&nbsp;products without violating federal law. This distinction is crucial because it allows manufacturers to explore new formulations that combine the non-psychoactive properties of&nbsp;<a href="https://cannabis.net/blog/smoke/what-is-the-difference-between-a-spliff-a-joint-and-a-blunt-cannabis-101">CBD with traditional tobacco.</a>
<h3>The Rise Of CBD&nbsp;And Its Potential Benefits</h3>
CBD, or cannabidiol, is one of over 100 cannabinoids found in the cannabis plant. Unlike&nbsp;<a href="https://cannabis.net/blog/medical/what-is-thc-exactly-now-that-you-know-all-about-cbd">THC (tetrahydrocannabinol)</a>, which is responsible for the psychoactive effects commonly associated with marijuana, CBD does not produce a high. Instead, it has gained immense popularity due to its purported health benefits, including anxiety reduction, pain relief, anti-inflammatory properties, and potential neuroprotective effects.
As consumers become more health-conscious and seek alternatives to traditional pharmaceuticals, CBD has emerged as a viable option for many individuals looking to manage various health conditions. Its non-psychoactive nature makes it particularly appealing to those who wish to avoid the intoxicating effects of THC while still benefiting from the therapeutic properties of cannabis.
<h3>Potential Health Benefits Of CBD In Tobacco Products</h3>
<ul>
<li>Reduction in Cravings:&nbsp;By potentially inhibiting nicotine metabolism, CBD may help reduce cravings among smokers trying to quit or cut back on their tobacco use.</li>
</ul>
<ul>
<li>Anxiety Relief:&nbsp;Many smokers use cigarettes as a way to cope with stress or anxiety. Incorporating CBD into tobacco products could provide an alternative method for managing these feelings without resorting solely to nicotine.</li>
</ul>
<ul>
<li>Anti-inflammatory Properties: Research suggests that CBD may have anti-inflammatory effects that could counteract some of&nbsp;the harmful consequences of smoking.</li>
</ul>
<ul>
<li>Harm Reduction: The addition of CBD may make tobacco products less harmful by providing therapeutic benefits that could&nbsp;offset some negative health impacts associated with nicotine consumption.</li>
</ul>
Regulatory Considerations
Despite these promising developments, any products containing CBD would still require marketing authorization from the Food and Drug Administration (FDA) before they can be legally sold. The FDA&rsquo;s role in regulating hemp-derived products is crucial to ensuring consumer safety and product efficacy.
<h3>Public Health Implications</h3>
The potential introduction of CBD into tobacco products raises important public health considerations. While incorporating CBD may reduce some harmful effects associated with traditional smoking, it is crucial to assess whether this combination could inadvertently encourage smoking behavior among new users or young people.
Public health advocates will need to monitor these developments closely to ensure that any new products do not undermine efforts to reduce smoking rates or promote healthier alternatives. Additionally, ongoing research will be necessary to evaluate the long-term effects of using CBD in conjunction with nicotine.
<h3>Current Regulatory Landscape</h3>
As it stands, hemp-derived CBD is legal at the federal level due to the 2018 Farm Bill, which legalized hemp cultivation and removed hemp-derived products containing&nbsp;<a href="https://cannabis.net/blog/opinion/under-0.3-thc-by-net-weight-the-greatest-loophole-in-drug-law-history">less than 0.3% THC from Schedule I classification</a>. However, this legalization does not automatically grant approval for all hemp-derived products; they must still comply with FDA regulations regarding safety and labeling.
The FDA has expressed concerns ove&rdquo; unregulated CBD products flooding the market without proper testing or oversight. As such, manufacturers seeking to incorporate CBD into tobacco products will need to navigate a complex regulatory landscape while ensuring compliance with all applicable laws.
<h3>Potential Challenges Ahead</h3>
While the prospect of combining CBD with tobacco presents exciting opportunities, several challenges remain:
<ol>
<li>
Regulatory Hurdles: The FDA&rsquo;s approval process can be lengthy and complex. Manufacturers will need to demonstrate that their products meet safety standards and provide adequate labeling information.
</li>
<li>
Consumer Education: As CBD-infused tobacco products enter the market, educating consumers about their benefits and potential risks will be essential. Misunderstandings about CBD may lead to skepticism or misuse.
</li>
<li>
Market Competition: The tobacco industry is highly competitive; introducing new products requires significant investment in marketing and distribution channels.
</li>
<li>
Quality Control: Ensuring consistent quality across different batches of CBD-infused tobacco products will be critical for maintaining consumer trust and safety.
</li>
<li>
Public Health Concerns: While integrating CBD into tobacco may offer some benefits, there are concerns that it could inadvertently encourage smoking behavior among new users or young people who might view these products as safer alternatives.
</li>
</ol>
<h3>Conclusion</h3>
The report from the Congressional Research Service highlights a significant shift in how we might view the intersection between cannabis and tobacco industries if marijuana is rescheduled from Schedule I status under federal law. Such changes could pave pathways toward innovative product development incorporating hemp-derived ingredients like cannabidiol (CBD) within traditional smoking contexts&mdash;ultimately reshaping consumer choices while addressing pressing public health concerns related directly tied back towards smoking-related harms.
As stakeholders navigate this evolving landscape&mdash;collaboration between regulators researchers manufacturers&mdash;and public health officials will prove vital moving forward towards creating safe effective options available across diverse populations seeking healthier alternatives amidst ongoing challenges presented by both industries&rsquo; histories intertwined within broader societal contexts surrounding drug policy reform overall! By prioritizing safety efficacy through rigorous research transparent communication consumers, this new frontier product development holds promise leading healthier lifestyles across America&rsquo;s diverse population seeking better choices today.
This article is from an external unpaid contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Cannabis

Government

Regulations

General

Rescheduling Cannabis Could Allow For Hemp Tobacco Cigarettes, But Not Weed And Tobacco Mixtures: No Spliff For You!

Biggest stock movers today: DJT, SEDG, EPAC and more

Enerpac Tool Group Corp. (EPAC) Q3 2024 Earnings Call Transcript

Earnings week ahead: PepsiCo, Delta Air Lines, JPMorgan, Citigroup and more

Enerpac Tool declares $0.04 dividend

Enerpac Tool Group: The Upside Might Be Fully Priced In

Enerpac Tool Group names Darren Kozik as CFO

Enerpac Tool Group ( ($EPAC) ) has issued an announcement. Enerpac Tool Group Corp. has appointed Darren M. Kozik as Executive Vice President and C...

Enerpac Tool Group Names New CFO Darren Kozik

Enerpac Tool Non-GAAP EPS of $0.50 misses by $0.03, revenue of $159M beats by $2.3M

Enerpac Tool Group Corp. (EPAC) Q4 2024 Earnings Call Transcript

BlackRock spotlights investment opportunities in Japan, China, and U.K.

AFAR

AIRE

ASHR

BBJP

BSET

BSVN

BYRN

CCEL

CHIQ

CNYA

CQQQ

CWEB

CXSE

DBJP

DJTWW

DXJS

EDUC

EPAC

ERIC

ETWO

EVGR

EWJV

EWUS

FAST

FLGB

FLJH

FLJP

FNGR

GDST

HELE

HEWJ

HIFS

JPXN

KLIP

KRUS

KWEB

LEDS

LEXX

MANU

MCHI

NRIX

NTIC

NVOS

PCYO

POOL

PSMT

SEDG

UPXI

VIST

VOXX

WDFC

XAIR

YANG

YINN

Press Releases

Enerpac Tool Group Schedules Second Quarter Fiscal 2024 Earnings Release and Conference Call

Enerpac Tool Group Reports Third Quarter Fiscal 2024 Results

Management

Enerpac Tool Group Announces Eric Chack Appointed EVP – Operations

Dividends

Enerpac Tool Group Announces Dividend

Enerpac Tool Group Announces Acquisition of DTA

Enerpac Tool Group Schedules Fourth Quarter Fiscal 2024 Earnings Release and Conference Call

Enerpac Tool Group Announces Darren Kozik Appointed EVP & Chief Financial Officer

Enerpac Tool Group Reports Fourth Quarter and Full-Year Fiscal 2024 Results; Introduces Full-Year Fiscal 2025 Outlook

CORRECTION -- Enerpac Tool Group Reports Fourth Quarter and Full-Year Fiscal 2024 Results; Introduces Full-Year Fiscal 2025 Outlook

STRATTEC SECURITY CORPORATION Appoints Matthew Pauli as Chief Financial Officer Effective November 13, 2024

Comments

Enerpac Tool Group

Enerpac Tool Group (EPAC) Opciones

Enerpac Tool Group (NYSE:EPAC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL